Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis USD Growth in Rest of World: 69.0% in FY2025, down 229.0 pts from a year earlier.
Latest, FY2025
69.0%
Period ended Dec 31, 2025
Change on a year earlier
-229.0 pts
298.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Pluvicto | Oncology | PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane | 1 596 | 38 | 398 | 69 | 65 | 1 994 | 43 | 42”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | USD Growth in Rest of World (% USD) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 69.0% | -229.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 298.0% | +87.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 211.0% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Cite this data
StockData. (2026). Novartis USD Growth in Rest of World (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-pluvicto-row-yoy-usd-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.